Influence of the level of insulin-like growth factor-I and endostatin in blood serum on the lipid profile indicators in patients with acute myocardial infarction and obesity

Abstract

The levels of insulin-like growth factor I and endostatin in the blood serum and their relationship with lipid profile were investigated in patients with acute myocardial infarction and obesity. The object of the study was 105 patients. All patients were divided into two groups: group 1 consisted of patients with AMI and concomitant obesity (n=60), group 2 consisted of AMI patients without obesity (n=45). The control group consisted of 20 practically healthy people. The average age of patients in group 1 was (67.44±1.34) years old, and in group 2 was (66.85±1.72) years old. The content of IGF-I and endostatin was determined by the enzyme immunoassay. To determine IGF-I, an enzyme-linked immunosorbent assay was used using the Human Insulin like growth factor-I ELISA Kit (MEDIAGNOST, Germany). The endostatin level was determined by the enzyme immunoassay using the Endostatin Elisa Kit (BIOMEDICA, Austria). The biochemical study included the determination of the level of TC and HDL, carried out by the peroxidase method using a set of reagents «Cholesterol Liquicolor» from «Human» (Germany) in blood serum stabilized with heparin. The obtained correlations indicate that an increase in the level of endostatin in the blood serum is significantly associated with an increase in the levels of TC, LDL, TG, CA and a decrease in HDL. Also, reliable data were obtained on the feedback between IGF-I and the level of TC, LDL, TG and CA, as well as a direct relationship between the indicators of IGF-I and HDL. The data obtained indicate that endostatin as a marker of angiogenesis is associated with obesity and dyslipidemia, and also indicate the anti-inflammatory and antioxidant properties of IGF-I under conditions of high autoimmune activity.